Mersana Therapeutics (MRSN) Tops Q4 EPS by 5c

Mersana Therapeutics (NASDAQ: MRSN) reported Q4 EPS of ($0.16), $0.05 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $10.7 million versus the consensus estimate of $9.1 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• BAE Systems Plc (BA:LN) (BAESY) New Top Pick in EU Defence at Morgan Stanley
• H.B. Fuller makes £715M cash offer to acquire Advanced Medical Solutions